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A collaborative survey was performed to compare prescribing strategies for the treatment of epilepsy in Mediterranean countries, 
based on analysis of 500 questionnaires compiled by physicians in 14 different countries. For partial seizures, carbamazepine was 
the drug of choice in most countries, whereas the second choice of drug differed widely. For primarily generalized tonic-clonic 
seizures, valproic acid was usually preferred, but other drugs used widely in some countries included phenobarbital, phenytoin 
and carbamazepine. Lamotrigine was the most popular second-line drug for primarily generalized tonic-clonic seizures in the 
European countries. In patients where the initial drug failed, switching to an alternative monotherapy was usually the preferred 
strategy, but advocates of early use of combination therapy exceeded 30% in the respondents of seven countries. Most respondents, 
in all countries except Turkey, did not prescribe drugs to prevent recurrence of febrile seizures; however, intermittent prophylaxis 
with a benzodiazepine was advocated by a considerable number of physicians, and continuous prophylaxis was prescribed by a 
significant minority of respondents in France, Syria and Tunisia. New drugs were rarely used as first-line treatment due to high 
cost and inadequate experience. Overall, this survey indicates that there is a wide variability in therapeutic practices between and 
within countries. This information may be useful for the implementation of national educational activities and for the design of 
pragmatic trials aimed at comparing different therapeutic strategies. 
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INTRODUCTION 
Choice of treatment of epilepsy is influenced by many 
factors. These include efficacy of the various drugs in 
different seizure types and syndromic forms, their com- 
parative tolerability profile, interactive potential and 
ease of use, factors related to the characteristics of the 
patient, and cost and reimbursability considerations”‘. 
However, cost-benefit ratios of different treatments are 
difficult to quantify objectively5, and individual per- 
ceptions about the comparative value of the various 
drugs differ considerably. Therapeutic strategies may 
vary widely from one country to anotherG9 depending 
on the structure of the national health system, socio- 
cultural background, drug availability and, not least, 
commercial pressure. Because of its extreme diver- 
sity in social, cultural and medical background, the 
Mediterranean region offers a unique opportunity to 
study national differences in therapeutic practices and 
their relation to local factors. Since 1990, physicians 
from this region with a special interest in epilepsy have 
held regular meetings aimed at comparing their experi- 
ences and building a collaborative network to improve 
the care of people with epilepsy. Within the framework 
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of these activities, it was considered of interest to com- 
pare therapeutic practices in this area. The survey saw 
participation from almost 500 physicians from over 10 
countries, and its results are summarized in this report. 
MATERIALS AND METHODS 
The survey was conducted between January and 
November 1997 and involved distribution of a ques- 
tionnaire designed to evaluate the pattern of prescrip- 
tion of antiepileptic drugs by individual doctors in dif- 
ferent situations. Prior to distribution, the questionnaire 
was translated into the local language and mailed by a 
national coordinator to all physicians known to have 
an active interest in the management of epilepsy. In 
some countries with an established chapter of the In- 
ternational League against Epilepsy (Algeria, France, 
Greece, Israel, Italy, Spain, Tunisia and Turkey), mail- 
ing was extended to all members of the chapter. Al- 
though these could include personnel not directly in- 
volved in clinical management, return of question- 
naires was solicited only from physicians active in the 
day-to-day treatment of patients with epilepsy. 
Specific issues addressed in the questionnaire in- 
cluded: (i) first-line and second-line drugs prescribed 
by the respondent for patients with partial seizures and 
primarily generalized tonic-clonic seizures; (ii) ther- 
apeutic strategy in patients refractory to initial treat- 
ment; (iii) management policy in children with uncom- 
plicated febrile convulsions; (iv) first-line and second- 
line utilization of new drugs, and attitude towards the 
use of new antiepileptic drugs in general. In addition, 
information was collected about the qualification, pro- 
fessional experience and working practice of each re- 
spondent. 
All questionnaires were forwarded to the central co- 
ordinators (EE and EP) for data processing and analy- 
sis. All results are reported descriptively. 
RESULTS 
Source of returned questionnaires 
A total of 500 questionnaires from 14 different coun- 
tries were returned (Table 1). The largest number of 
returns in absolute terms, with over 80 respondents, 
were from Italy, France and Tunisia. Responder rates 
as a percentage of distributed questionnaires was rather 
variable and ranged from 6% in Spain to 85% in Alge- 
ria. Only one questionnaire was returned from Albania, 
Egypt, Portugal and Yugoslavia and, accordingly, no 
results are provided for these countries. 
Respondents were mostly physicians aged 35 to 50 
years, though an appreciable proportion were older 
in Israel and younger in Syria and Turkey (Table 1). 
Most respondents were hospital-based neurologists. 
For Syria, questionnaires originated from a single uni- 
versity hospital in Damascus. 
Child neurologists were especially numerous in Italy, 
and paediatricians and psychiatrists accounted for the 
majority of respondents in Tunisia. The majority of 
practitioners reported seeing over 50 patients per year, 
but physicians seeing a smaller number of patients were 
especially common in Syria and Tunisia. 
Comparison of therapeutic practices 
Treatment of partial seizures 
For the first-line management of partial seizures, car- 
bamazepine was the preferred drug, with over 80% 
preference in most countries (Fig. 1). Exceptions were 
Tunisia, where carbamazepine and valproate were sim- 
ilarly popular, and Malta, where four out of five respon- 
dents favoured phenytoin as a first choice. In France, 
Italy and Tunisia, preferential use of valproic acid was 
somewhat more common among paediatricians and 
paediatric neurologists compared to physicians treat- 
ing mainly adult patients. New antiepileptic drugs were 
rarely mentioned as first-line options, although seven 
out of 55 selections in Greece were for oxcarbazepine. 
Preferences for second-choice treatment differed 
widely (Fig. 2), the only consistent finding being the 
choice of valproic acid in over a third of respondents in 
most countries. Phenytoin was chosen by a consider- 
able number of physicians in Israel, Syria and Turkey, 
whereas vigabatrin was the preferred second-line agent 
in about a third of respondents in France, Italy and 
Malta. Overall, new antiepileptic drugs were selected 
for second-line treatment in 67 (48%) out of 140 pref- 
erences in Italy, 34 (35%) out of 96 in France, two (6%) 
out of 31 in Israel, nine (43%) out of 21 in Spain and 
23 (47%) out of 49 in Greece. 
Treatment of primarily generalized tonic-clonic 
seizures 
Valproic acid was the preferred first-line treatment by 
the vast majority of respondents in Algeria, France, 
Greece, Italy, Spain and Turkey, and it was also a pop- 
ular choice in all other countries except Syria (Fig. 3). 
Other drugs mentioned frequently included pheno- 
barbital (Algeria, Italy, Tunisia and Syria), phenytoin 
(Greece, Israel, Malta, Turkey and Syria) and carba- 
mazepine (Israel, Syria and Turkey). The new drugs 
lamotrigine and oxcarbazepine were selected by only 
three and eight respondents respectively out of a total 
of 500. 
Preferences for second-line treatment showed re- 
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Table 1: Characteristics of respondents in the countries participating in the survey. Some questions were answered only by some 
of the resoondents. 
Algeria France Greece Israel Italy Malta Spain Syria lImisia Turkey 
Number of auestionnaires distributed 20 320 300 80 1156 8 350 160 300 100 
Number of rkspondents 
Age 
Private clinic 
t35years 
35-50years 
>50years 
Speciality 
Neurologist 
Paediatrician 
Psychiatrist 
Neuropaediatrician 
Other 
Number of patients seen yearly 
<IO 
1 O-50 
51-100 
>I00 
Affiliation 
Hospital 
Community 
17 90 52 27 132 5 21 26 89 37 
6 7 9 0 II 2 2 15 16 17 
II 53 35 13 90 3 15 9 62 16 
0 30 8 13 30 0 4 2 7 4 
13 67 44 25 88 
0 4 I 2 0 
2 6 5 0 2 
1 12 6 5 43 
0 2 0 0 4 
0 2 0 0 4 
1 12 19 7 23 
0 22 15 I1 26 
14 54 17 8 75 
16 
0 
60 
30 
36 
14 
25 
0 
115 
29 1 
5 20 21 
7 8 
39 
51 
34 
I 
8 
8 6 4 15 0 1 0 0 0 
14 16 17 30 
0 0 35 2 
0 4 33 0 
7 0 2 5 
0 6 2 0 
0 4 22 0 
0 5 .27 3 
0 9 13 9 
19 8 25 24 
CBZ 
CBZ 83% 
82% 
81% 94% 
OVN 
CBZ CBZ 
CBZ 46% 89% 
C 
8 
HT 
1% 
VPA 
8% 2% 41% 11% 
Fig. 1: Drugs used preferentially for the first-line treatment of partial seizures (expressed as percentage of respondents) in the 
countries included in the survey. Abbreviations: BZD = benzodiazepines; CBZ = carbamazepine; GBP = gabapentin; LTG = 
lamotrigine; OXC = oxcarbazepine; PB = phenobarbital; PHT = phenytoin; VGB = vigabatrin; VPA = valproic acid. 
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VGB 33% 
CBZ 
12% BZD 1% 
PHT 10% 
PRh4 I% 
PB 3% 
VPA 40% 
38% 
CBZ 5% 
PHT 
9% 
VPA 42% 
LTG 
24% 
VPA 
43% 
VGB CBZ 
19% 5% 
VGB 36% 
CBZ 
35% 
VPA 
44% 
GBP 
16% 
VGB 
6% 
VGB 
40% 
CBZ 
Fig. 2: Drugs used preferentially for the second-line treatment of partial seizures (expressed as percentage of respondents) in the 
countries included in the survey. PRM = primidone; TPM = topiramate; other abbreviations as in Fig. 1. 
VPA 
65% 
VPA 
98% 
_ PB 
2% 
CBZ 
6% 
oxc 
15% 
Pt3 
CBZ 35% 
PHT 
VPA 
34% 
I I% 
PHT 
34% 
VPA 
84% 
VPA 
VPA VPA 60% 
VPA 
BZD CBZ 
2% 3% 
PB CBZ 
II% 13% 
PB PB PHT 3% 
49% 3% 13% 
Fig. 3: Drugs used preferentially for the first-line treatment of primarily generalized tonic-clonic seizures (expressed as 
percentage of respondents) in the countries included in the survey. Abbreviations as in Figs 1 and 2. 
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PB CBZ 
4% 8% 
PHT 
18% 
PB 
51% 
VPA 
18% CBZ CBZ 39% 
PB 
ET.5 1% 
BZD 3% 
PHT 6% 
PRhd 1% 
PB 
VPA2% 
LTG 21% 
VGB 1% 59% 
PRM 
4% VPA 
BZD 
I% 
CBZ 
PB 
8% 
PHT 
28% 
VPA 
45% 
PB 
35% 
CBZ 
I 0% 
PHT 
4% 
VPA 
14% 
LTG 
24% 
LTG 
PHT 
23% 
PB 
HT 
3% 
VPA 
21% 
CBZ 
21% 
Fig. 4: Drugs used preferentially for the second-line treatment of primarily generalized tonic-clonic seizures (expressed as 
percentage of respondents) in the countries included in the survey. No data are reported for Israel because this question was not 
answered by the majority of respondents in that country. ETS = ethosuximide; other abbreviations as in Figs 1 and 2. 
markable variation (Fig. 4). Widely favoured options 
were phenobarbital (Algeria, France, Italy, Tunisia 
and Turkey), lamotrigine (France, Greece, Italy and 
Spain), phenytoin (Greece, Spain and Syria) and car- 
bamazepine (France, Malta, Syria and Turkey). As ex- 
pected, valproic acid was a common second choice for 
those respondents who did not indicate it as first choice. 
Strategies in patients failing on initial monotherapy 
Where asked to indicate their preferred approach in 
patients where initial monotherapy failed, physicians 
who favoured switching these patients to monotherapy 
with an alternative drug accounted for 33% of prefer- 
ences in Syria, 50% in Malta, 52% in Greece, 58% in 
Turkey, 59% in Algeria, 63% in Italy, 64% in Tunisia, 
69% in Israel, 71% in Spain and 77% in France. The 
remaining respondents indicated that they would add 
another drug to the pre-existing treatment. 
Prophylaxis against recurrence of febrile seizures 
The use of pharmacological prophylaxis against the 
recurrence of uncomplicated febrile seizures is sum- 
marized in Table 2. More than 50% of respondents in 
all countries except Turkey (47.2%) did not prescribe 
drugs to prevent febrile seizures. Intermittent prophy- 
laxis was used by an appreciable proportion of respon- 
dents in Algeria, France, Israel, Italy, Syria, Tunisia 
and Turkey: this involved mostly rectal administration 
of a benzodiazepine, though oral benzodiazepines were 
frequently used in Italy and Tunisia. Interestingly, a 
small number of physicians used intermittent prophy- 
laxis with valproic acid or phenobarbital. 
Continuous prophylaxis with valproate or phenobar- 
bital was prescribed by a relative minority of respon- 
dents, especially in France, Syria and Tunisia. 
Attitude towards the use of new antiepileptic drugs 
The use of new drugs as initial treatment varied widely 
from one country to another. Many physicians, how- 
ever, did not provide an answer to this question, possi- 
bly because they did not consider the first-line use of a 
new drug to be acceptable. Among those who provided 
an answer, the proportion using a new drug as first-line 
in more than 10% of their patients (with number of re- 
spondents in brackets) ranged from 0% (17) in Algeria 
to 4% (78) in France, 11% (28) in Turkey, 10% (50) in 
Tunisia, 10% (20) in Israel, 12% (eight) in Syria, 16% 
(88) in Italy, 20% (20) in Spain and 34% (41) in Greece 
(plus one of four respondents from Malta). When asked 
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Table 2: Strategies concerning the use of pharmacological prophylaxis against recurrence of uncomplicated febrile seizures. Drug 
abbreviations as in Fig. 1. 
Algeria France Greece Israel Italy Malta Spain Syria Tunisia Turkey 
Number of respondents 17 82 46 25 124 3 20 23 78 36 
Prophylaxis not used 
Intermittent prophylaxis preferred 
VPA 
Oral BZD 
Rectal BZD 
BZD (route unspecified) 
PB 
Unspecified 
Continuous prophylaxis preferred 
VPA 
PB 
BZD 
LTG 
Unsoecified 
IO 47 
4 24 
1 I 
2 8 
1 11 
0 0 
0 0 
0 4 
3 11 
3 9 
0 I 
0 1 
0 0 
0 0 
41 18 86 3 18 13 
2 6 29 0 2 6 
0 0 0 0 0 1 
0 3 20 0 2 0 
1 I 8 0 0 1 
I 0 1 0 0 0 
0 0 0 0 0 4 
0 2 0 0 0 0 
3 1 9 0 0 4 
I I 8 0 0 0 
0 0 1 0 0 4 
0 0 0 0 0 0 
I 0 0 0 0 0 
1 0 0 0 n n 
43 
21 
15 
3 
0 
1 
14 
6 
0 
n 
17 
15 
2 
0 
II 
I 
0 
4 
to specify a situation where a new drug was felt to be in- 
dicated for first-line treatment, the single most common 
indication was vigabatrin for infantile spasms, but an 
appreciable proportion of respondents failed to provide 
an answer to this question. Overall, vigabatrin in West 
syndrome (with an indication sometimes restricted to 
subgroups, such as spasms associated with tuberous 
sclerosis) was specified by 25 out of 53 respondents 
in France; seven out of 20 in Greece, four out of 10 in 
Israel, 3 1 out of 90 in Italy, one out of three in Malta, 10 
out of 18 in Spain, one out of one in Syria, eight out of 
16 in Tunisia, and five out of 15 in Turkey. Other indi- 
cations mentioned by more than four respondents were 
vigabatrin for partial seizures, sometimes restricted to 
special subgroups (n = 9, France; n = 22, Italy), viga- 
batrin for epilepsy associated with tuberous sclerosis 
(n = 7, Italy; n = 7, Turkey), lamotrigine for par- 
tial seizures (n = 5, Italy) and for one or more types 
of generalized seizures or epilepsies (n = 13, France, 
n = 12, Italy) and felbamate for Lennox-Gastaut syn- 
drome (n = 13, Italy). 
The only countries where physicians rating the new 
drugs as more effective than older agents outnumbered 
those rating the new drugs as equally or less effective 
were Algeria, Syria and Tunisia, an interesting finding 
because these were the countries in which new drugs 
are either not available (Algeria, Syria) or least used 
(Tunisia). In all countries, new drugs were generally 
perceived as being better tolerated than older agents, 
the only exception being Malta where none of the three 
respondents rated the new drugs as superior in terms of 
tolerability. High cost and inadequate experience were 
rated consistently as the main factors limiting the pre- 
scription of new drugs. Interestingly, worry about side 
effects was not considered a major issue, being men- 
tioned by less than 10% of overall respondents. 
DISCUSSION AND CONCLUSIONS 
This survey provides an interesting comparison of the 
utilization of antiepileptic drugs in the Mediterranean 
region. Because of the relatively small proportion of 
respondents in some countries, results may not be fully 
representative of national situations, yet they are likely 
to reflect a segment of the most motivated physicians 
involved in the treatment of epilepsy in different ge- 
ographical areas. Respondents covered a wide range 
of qualifications, from paediatricians to adult neurolo- 
gists, some with a specialized interest in epilepsy and 
others with a broader experience in general neurology. 
The distribution of these qualifications differed some- 
what from country to country, an observation which 
should be taken into consideration when comparing 
respective therapeutic practices. 
The main issues covered in this survey addressed ba- 
sic decisions concerning clinical management. One is 
the choice of drugs for the newly diagnosed patient. 
Based on available evidence, carbamazepine, valproic 
acid, phenytoin and phenobarbital show similar effi- 
cacy against partial seizures and secondarily general- 
ized tonic-clonic seizures’0-‘8, and these drugs were 
mentioned as first-line options by most of our respon- 
dents. Carbamazepine was the most popular choice 
for partial seizures, presumably because it is often re- 
garded as having more favourable tolerability com- 
pared to some of the other drugs3. In recent years, 
however, valproic acid has been found to be similarly 
effective and well tolerated in partial epilepsy4* I67 ‘*, 
which may explain its relative popularity in Tunisia, 
particularly among paediatricians, and, more gener- 
ally, its preferential role as a second-line agent in most 
countries. Phenytoin is a common choice in English 
speaking countries6~s and, accordingly, it was pre- 
ferred for the first-line treatment of partial seizures by 
four out of the five Maltese respondents in our survey. 
For patients with primarily generalized tonic-clonic 
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seizures, valproic acid was preferred in most coun- 
tries, although phenytoin, carbamazepine and pheno- 
barbital were also used relatively widely. Valproate, 
phenytoin, carbamazepine and phenobarbital produced 
similar remission rates in controlled trials in these 
patients ‘“~12~13*‘~‘8, though preferential use of val- 
proic acid may be justified by the observation that some 
of the other drugs, most notably carbamazepine, are in- 
effective and may even aggravate other seizure types 
(particularly absences and myoclonic seizures) which 
often coexist in epileptic syndromes associated with 
primarily generalized seizures4* 19. 
Another issue investigated was the strategy in pa- 
tients where initial monotherapy failed. In the past, it 
was believed that combination therapy had many ad- 
vantages, and polypharmacy was widely used in the 
early stages of treatment2’. In the last two decades, 
however, the merits of monotherapy have been widely 
demonstrated2’*22, and recent studies suggest that up 
to 40-50% of patients where the initial prescribed drug 
failed may achieve freedom from seizures by switch- 
ing to monotherapy with an alternative agent23-25. This 
was probably recognized by the numerous physicians 
who favoured alternative monotherapy in these pa- 
tients. Advocates of combination therapy, however, 
were present in all countries, and a proportion of re- 
spondents ranging from 21% in Israel to 67% in Syria 
stated that their usual policy is to add a second drug 
when initial monotherapy fails. There is no doubt that 
some patients where sequential monotherapies failed 
may do well on a drug combination, but how early 
polytherapy should be tried is obviously a matter of 
controversy among practising physicians’*26. 
In recent years, evidence has accumulated that recur- 
rence of simple uncomplicated febrile seizures does not 
increase the risk of subsequent epilepsy, and therefore 
continuous pharmacological prophylaxis is generally 
not indicated in these patients27*28. Most physicians 
in our survey complied with this recommendation, al- 
though in some countries continuous prophylaxis is 
still prescribed by an appreciable number of practition- 
ers. Intermittent prophylaxis with oral29 or, preferably, 
recta128*30 diazepam is a reasonable option in some pa- 
tients and was frequently adopted in some countries. On 
the other hand, there seems to be no rationale for inter- 
mittent use of phenobarbital or valproic acid27, which 
were advocated by a small number of respondents. 
One section of the questionnaire was devoted to the 
attitude towards the use of new drugs. In all coun- 
tries surveyed, new drugs were very rarely mentioned 
as agents of choice. However, vigabatrin was often 
preferred as a second-line treatment against partial 
seizures in France, Italy and Malta, whereas lamot- 
rigine was often indicated as a second-line treatment 
against primarily generalized seizures in most Euro- 
pean countries. When asked to specify a condition 
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where a new drug was felt to be indicated for first- 
line treatment, the most common indication was viga- 
batrin for infantile spasms, in agreement with sugges- 
tions made in the recent literature3’. Many physicians 
in Italy mentioned felbamate for Lennox-Gastaut syn- 
drome, a surprising finding because first-line use of 
this drug is not an approved indication due to the risk 
of aplastic anaemia and liver toxicity3’. Overall, the 
survey revealed some scepticism towards the value of 
new drugs, although there was a common perception 
that the latter may offer some advantages in tolerabil- 
ity. Interestingly, new drugs were considered to be more 
effective than older agents by a high proportion of re- 
spondents only in North African countries, where new 
drugs are either not available or least used. In agreement 
with recent concems32, cost was widely considered a 
major factor limiting use of the new agents. 
In conclusion, this survey provides a general 
overview of prescribing practices among physicians 
treating epilepsy in Mediterranean countries. Some 
similarities between countries were observed, but there 
were also differences which could not entirely be as- 
cribed to local availability of drugs or their cost. Sig- 
nificant differences between individual physicians, as 
well as some inappropriate or questionable therapeutic 
practices, were also evident within individual coun- 
tries. These results may be useful for the planning of 
further drug utilization studies, for the implementation 
of educational activities at national and international 
level, and for the design of trials aimed at comparing 
different therapeutic approaches. 
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